The sun is out and we’re excited to be going live with an opportunity this morning.
The deal will include 1:1 long dated listed options.
Keep an eye on your inbox!
Across markets
Australian shares are poised for a modest opening advance. Shares slipped in New York as techs reversed, paced by Nvidia, and US bond yields surged higher after retail sales pointed to resilient consumer demand and the prospect that rates may need to rise still higher.
ASX futures were up 12 points or 0.2% to 7092 near 6.40am AEDT, paring earlier gains in line with New York’s afternoon weakness.
REA Group is set for an active session after activist investor Starboard Value LP pressed News Corp to sell its 61 per cent stake in the Australian real estate listings company.
- On Wall St at 3.50pm: Dow -0.1% S&P -0.2% Nasdaq -0.5%
- In New York: BHP +0.9% Rio +0.4% Atlassian +0.4%
- Tesla +0.1% Apple -1.1% Amazon -1.1% Nvidia -4.8%
“The US consumer appears to be much stronger than anyone thought on Wall Street,” Oanda’s Edward Moya said, referring to the latest retail sales data. The advance estimate for retail sales in September rose 0.7 per cent, more than twice the 0.3 per cent consensus estimate.
Wells Fargo’s economics team said: “We have long stressed that real income is the last major driver of spending, and continued labour market tightness suggests income can continue to fuel consumption in the near term.”
Source: AFR
- Biotech investment fund reckons sector is poised for growth but Australia not ready to capitalise on growth
- Per capita, Australia leads biomedical research productivity but invests substantially less in commercialisation
- Several factors driving ASX biotech downturn in 2023 beyond economic uncertainty and global geopolitical tensions
A leading Australian biotech investment fund reckons the sector is poised for a significant upswing but the country lags in the race to capitalise on potential growth.
Returning from one of his regular trips to the US, HB Biotechnology managing director Charles Williams told Stockhead
These reasons include:
Innovation and Breakthroughs
“Never before have there been so many tools at our disposal to fight disease,” Williams says.
“Globally, biotech companies are focusing on cutting-edge research and development in areas from gene editing, RNA therapeutics, to personalised medicine and novel radiotherapeutics.”
High Growth Potential
“The sector often experiences rapid growth, driven by advancements in medical science, increasing demand for healthcare solutions, and a growing aging population,” Williams says.
Unmet Medical Needs
“In harnessing new technologies and new financial incentives, many biotech companies are dedicated to addressing unmet medical needs, including rare diseases and conditions that lack effective treatments,” he says.
Diversification Potential
“Using listed biotech indices as a proxy, the biotech sector has one of the lowest correlations with broader market indices compared to any other sector, a characteristic that is enviable in any diversified investment portfolio.”
Source: Stockhead
Company: Alderan Resources (ASX:AL8)
Sector: Lithium
Deal Type: Placement
Raise Amount: $1.75M
Latest Entry Price: $0.006 with a 1:2 AL8OA
Today’s Price Change: $0.013 -13.33%
Company: Terra Uranium (ASX:T92)
Sector: Uranium
Deal Type: IPO
Raise Amount: $7.5M
Latest Entry Price: $0.20
Today’s Price Change: $0.14 Unchanged
Company: Patagonia Lithium (ASX:PL3)
Sector: Lithium
Deal Type: IPO
Raise Amount: $8.6M
Latest Entry Price: $0.20
Today’s Price Change: $0.15 Unchanged
Company: Gold Mountain Limited (ASX:GMN)
Sector: Lithium
Deal Type: Placement
Raise Amount: $2.25M
Latest Entry Price: $0.0075
Today’s Price Change: $0.005 -9.09%
Company: Unith Ltd. (ASX:UNT)
Sector: AI/ChatGPT
Deal Type: Placement
Raise Amount: $4.5M
Latest Entry Price: $0.033 with a 1:1 UNTO
Today’s Price Change: $0.0215 -6.52%
Company: Volt Resources Ltd. (ASX:VRC)
Sector: Battery Metals
Deal Type: Placement
Raise Amount: $5.75M
Latest Entry Price: $0.011
Today’s Price Change: $0.008 Unchanged
Company: Castle Minerals Ltd. (ASX:CDT)
Sector: Battery Metals/Base Metals
Deal Type: Placement
Raise Amount: $1.52M
Latest Entry Price: $0.02 with a 2:3 CDTOA
Today’s Price Change: $0.009 Unchanged
Company: Avenira Ltd. (ASX:AEV)
Sector: Phosphate
Deal Type: Placement
Raise Amount: $2.1M
Latest Entry Price: $0.01 with a 1:2 AEVO
Today’s Price Change: $0.01 Unchanged
Company: Latrobe Magnesium Ltd. (ASX:LMG)
Sector: Magnesium
Deal Type: Placement
Raise Amount: $3M & $11.5M
Latest Entry Price: $0.10 with a 1:4 LMGO
Today’s Price Change: $0.043 -4.44%
Company: Askari Metals Ltd (ASX:AS2)
Sector: Mining
Deal Type: IPO
Raise Amount: $5.7M
Latest Entry Price: $0.35 with a 1:3 AS2O
Today’s Price Change: $0.185 +2.78%
Company: iCandy (ASX:ICI)
Sector: Gaming & Digital Advertising
Deal Type: Placement
Raise Amount: $1.25M
Latest Entry Price: $0.02 with a 1:1 ICIOB
Today’s Price Change: $0.035 +2.94%
Company: Fatfish Group (ASX:FFG)
Sector: Fintech
Deal Type: Placement
Raise Amount: $1.5M
Latest Entry Price: $0.015 with a 1:2 FFGOA
Today’s Price Change: $0.01 -9.09%
Company: Paradigm Biopharma (ASX:PAR)
Sector: Biopharma
Deal Type: IPO Cornerstone
Raise Amount: $1M+
Latest Entry Price: $0.35
Today’s Price Change: $0.63 Unchanged
Company: ReNu Energy Limited (ASX:RNE)
Sector: Energy
Deal Type: Placement
Raise Amount: $1.46M
Latest Entry Price: $0.06 with a 1:1 RNEO
Today’s Price Change: $0.026 -7.14%
Company: Carly Holdings Ltd (ASX:CL8)
Sector: AI and Car subscription
Deal Type: Placement
Raise Amount: $1.25M
Latest Entry Price: $0.025 with a 1:2 CL8O
Today’s Price Change: $0.018 +5.88%
Company: Avecho Biotechnology (ASX:AVE)
Sector: CBD
Deal Type: Placement
Raise Amount: $5M
Latest Entry Price: $0.006 with a 3:2 AVEOA
Today’s Price Change: $0.0045 Unchanged
Company: ECS Botanics Holdings Ltd (ASX:ECS)
Sector: Medicinal Cannabis
Deal Type: Placement
Raise Amount: $6.6M
Latest Entry Price: $0.033 with 1:2 ECSO
Today’s Price Change: $0.025 +4.17%
If you would like more information on future Peak deals, please don’t hesitate to get in touch.
Peak on 1300 304 460
No responses yet